» Articles » PMID: 27366477

What Do Current Information and Evidence Suggest to Us for Oxytocin Use During Caesarean Section?

Overview
Specialty Anesthesiology
Date 2016 Jul 2
PMID 27366477
Authors
Affiliations
Soon will be listed here.
Abstract

Oxytocin is the first-line agent in the prevention and treatment of uterine atony and maintenance of uterine tone. Since there are several different practices related to the use of oxytocin during caesarean sections, we would like to address the latest information and evidence for rational oxytocin use.

References
1.
Thomas J, Koh S, Cooper G . Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesth. 2006; 98(1):116-9. DOI: 10.1093/bja/ael302. View

2.
Tsen L, Balki M . Oxytocin protocols during cesarean delivery: time to acknowledge the risk/benefit ratio?. Int J Obstet Anesth. 2010; 19(3):243-5. DOI: 10.1016/j.ijoa.2010.05.001. View

3.
Sarna M, Soni A, Gomez M, Oriol N . Intravenous oxytocin in patients undergoing elective cesarean section. Anesth Analg. 1997; 84(4):753-6. DOI: 10.1097/00000539-199704000-00010. View

4.
Carvalho J, Balki M, Kingdom J, Windrim R . Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol. 2004; 104(5 Pt 1):1005-10. DOI: 10.1097/01.AOG.0000142709.04450.bd. View

5.
Dyer R, van Dyk D, Dresner A . The use of uterotonic drugs during caesarean section. Int J Obstet Anesth. 2010; 19(3):313-9. DOI: 10.1016/j.ijoa.2010.04.011. View